Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation Combined With Camrelizumab in Advanced or Unresectable Soft Tissue Sarcoma
NCT07602049Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in soft tissue sarcoma (STS), osteosarcoma (OS), sponsored by Sun Yat-sen University. Started Nov 2024; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07602049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602049.